Search

Displaying results 1101 - 1110 of 3180 in total
  1. Drug

    Bortezomib

    go.drugbank.com/drugs/DB00188
    ApprovedInvestigational

    Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome ...

    Synonyms: N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamideCategories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  2. Drug

    Selicrelumab

    go.drugbank.com/drugs/DB14958
    Investigational

    Selicrelumab is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100).

  3. Drug

    RWJ-800088

    go.drugbank.com/drugs/DB18693
    Investigational

    RWJ-800088 is a synthetic PEGylated thrombopoietin (TPO) mimetic (TPOm) peptide with no sequence homology to endogenous TPO.

    Synonyms: -METHOXY-, 1,1'-DIETHER WITH N2,N6-BIS(N-(3-HYDROXY-1-OXOPROPYL)-L-ISOLEUCYL-L-.ALPHA., a synthetic PEGylated thrombopoietin (TPO) mimetic (TPOm) peptide with no sequence homology to endogenous
  4. Drug

    Trilaciclib

    go.drugbank.com/drugs/DB15442
    ApprovedInvestigational

    Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  5. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    Omaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory properties. Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mit...

    Synonyms: Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-Categories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 Substrates
  6. Drug

    PF-05241328

    go.drugbank.com/drugs/DB15124
    Investigational

    PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound

  7. Drug

    Liotrix

    go.drugbank.com/drugs/DB01583
    Approved

    Administration of levothyroxine alone is sufficient for maintaining serum T4 and T3 levels in most patients and combination hormone replacement therapy generally offers no therapeutic advantage.

    Categories: P-glycoprotein inducers, Cytochrome P-450 Substrates
  8. Drug

    Oleic Acid

    go.drugbank.com/drugs/DB04224
    ApprovedInvestigationalVet approved

    An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed)

    Mixtures: NEUROGAIN PB VEGICAP CAPSULE 500MG
  9. Drug

    Ranirestat

    go.drugbank.com/drugs/DB05327
    Investigational

    Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels

  10. Drug

    Zolpidem

    go.drugbank.com/drugs/DB00425
    ApprovedInvestigational

    Zolpidem, also known as Ambien, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This dr...

    Synonyms: N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamideMixtures: Sentrazolpidem PM-5